论文部分内容阅读
目的观察坎地沙坦对早期糖尿病肾病患者炎症状态的影响。方法 70例糖尿病肾病患者,按随机数字表法分为对照组和观察组,各35例。对照组给予调脂、降糖及控制饮食等治疗,观察组在对照组基础上给予坎地沙坦治疗,比较两组治疗后疗效。结果两组治疗后血肌酐(Scr)、尿素氮(BUN)、肿瘤坏死因子(TNF)、白细胞介素-6(IL-6)及C-反应蛋白(CRP)水平均较治疗前有明显下降(P<0.05),且观察组下降程度均显著优于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论早期糖尿病肾病患者伴有炎性因子水平升高,坎地沙坦可降低CRP、TNF、IL-6的表达,抑制炎症反应,具有对肾功能保护作用。
Objective To investigate the effect of candesartan on the inflammatory status of patients with early diabetic nephropathy. Methods Seventy patients with diabetic nephropathy were divided into control group and observation group according to random number table method, 35 cases each. The control group was given lipid-lowering, hypoglycemic and diet control, the observation group was given candesartan on the basis of the control group, and the curative effect was compared between the two groups. Results Serum creatinine (Scr), blood urea nitrogen (BUN), tumor necrosis factor (TNF), interleukin-6 (IL-6) and C-reactive protein (CRP) (P <0.05), and the decrease in the observation group was significantly better than that in the control group (P <0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P> 0.05). Conclusions Patients with early diabetic nephropathy may be associated with elevated levels of inflammatory cytokines. Candesartan may reduce the expression of CRP, TNF and IL-6 and inhibit the inflammatory reaction, which may have a protective effect on renal function.